Literature DB >> 9525754

Magnetic resonance imaging relaxation times and gadolinium-DTPA relaxivity values in human cerebrospinal fluid.

M A Ibrahim1, J F Emerson, C W Cotman.   

Abstract

RATIONALE AND
OBJECTIVES: This study was conducted to prove the feasibility of using cerebrospinal fluid (CSF) T1 and T2 measurements to assess the blood-brain barrier integrity in disease states not noted for focal blood-brain barrier disruption, such as Alzheimer's disease.
METHODS: T1 and T2 of human CSF samples were measured with and without gadolinium Gd-DTPA over a concentration range of 1.98 x 10(-3) to 6.32 mM, in a GE 1.5-T Signa scanner.
RESULTS: T1 and T2 of human CSF without Gd-DTPA were measured as 2.39 and 0.23 s. K1 and K2 were calculated as 6.25 and 6.74 mM(-1) s(-1). The lowest Gd-DTPA concentration with measurable T1 and T2 was 1.98 x 10(-3) mM. There is no statistically significant difference in T2 and K2 at different repetition times.
CONCLUSIONS: This work demonstrates that a single measurement of relaxation times after contrast-enhanced magnetic resonance imaging could be used to determine the Gd-DTPA concentration in CSF. It may thus be feasible, using this technique, to measure intersubject and intraregional variability in the quantity of Gd-DTPA transferred across the blood-brain barrier after intravenous injection of contrast agent.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9525754     DOI: 10.1097/00004424-199803000-00005

Source DB:  PubMed          Journal:  Invest Radiol        ISSN: 0020-9996            Impact factor:   6.016


  2 in total

1.  Quantitative evaluation of oxygenation in venous vessels using T2-Relaxation-Under-Spin-Tagging MRI.

Authors:  Hanzhang Lu; Yulin Ge
Journal:  Magn Reson Med       Date:  2008-08       Impact factor: 4.668

2.  Use of dynamic contrast-enhanced MRI to measure subtle blood-brain barrier abnormalities.

Authors:  Paul A Armitage; Andrew J Farrall; Trevor K Carpenter; Fergus N Doubal; Joanna M Wardlaw
Journal:  Magn Reson Imaging       Date:  2010-10-27       Impact factor: 2.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.